Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | PNMT | P11086 | 1/20 | 0.39 |
| ▸ | CD44 | P16070 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.38 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA4 | P22748 | 3/20 | 0.38 |
| ▸ | CA7 | P43166 | 3/20 | 0.38 |
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16852846 | 0.88 | KEAP1 (0.47) | KEAP1HTR2CAOC3PNMTCD44 | |
| SCHEMBL16852799 | 0.86 | KEAP1 (0.46) | KEAP1HTR2CAOC3PNMTCD44 | |
| SCHEMBL29412515 | 0.80 | HTR2C (0.40) | KEAP1HTR2CPNMTCD44MAOB | |
| SCHEMBL29681708 | 0.78 | KEAP1 (0.44) | KEAP1GRIA2CA12CA1CA2 | |
| SCHEMBL61176 | 0.78 | KEAP1 (0.44) | KEAP1GRIA2CA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL7399331 | 0.77 | KEAP1 (0.43) | KEAP1GRIA2CA12CA1CA2 | |
| SCHEMBL16852807 | 0.73 | CA1 (0.39) | KEAP1HTR2CGRIA2PDPK1CA12 | |
| SCHEMBL25320318 | 0.73 | CA1 (0.47) | KEAP1HTR2CAOC3GRIA2PARP1 | |
| SCHEMBL22726002 | 0.73 | AOC3 (0.47) | KEAP1AOC3MAOBCA12CA1 | |
| SCHEMBL21266522 | 0.73 | CA1 (0.49) | KEAP1AOC3GRIA2PARP1PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7727997-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | claimed |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | ELAN PHARMACEUTICALS, INC. | 2007-09-13 | — | — | US | claimed |
| US-20040171881-A1 | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives | PHARMACIA & UPJOHN COMPANY | 2004-09-02 | — | — | US | claimed |
| EP-0082217-A1 | Ammonium salts, process for their preparation, pharmaceutical preparations containing them and their use | CIBA-GEIGY AG (CH) | 1983-06-29 | — | — | EP | claimed |
| US-4327091-A | ANTIINFLAMMATORY AGENTS | CIBA-GEIGY CORPORATION (US) | 1982-04-27 | — | — | US | claimed |
| EP-0003360-B1 | AZATHIANAPHTHALENE DERIVATIVES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND THEIR UTILISATION | CIBA-GEIGY AG (CH) | 1981-12-30 | — | — | EP | claimed |
| US-4213980-A | ANTIINFLAMMATORY AGENTS | CIBA-GEIGY CORPORATION (US) | 1980-07-22 | — | — | US | claimed |
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| EP-3116851-B1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | SALK INST FOR BIOLOGICAL STUDI (US) | 2023-07-26 | — | — | EP | disclosed |
| US-20230134822-A1 | AMINE COMPOUND, CHEMICALLY AMPLIFIED RESIST COMPOSITION, AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-05-04 | — | — | US | disclosed |
| US-20230137472-A1 | CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-05-04 | — | — | US | disclosed |
| US-20230137472-A1 | CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-05-04 | — | — | US | disclosed |
| EP-0003360-B1 | AZATHIANAPHTHALENE DERIVATIVES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND THEIR UTILISATION | CIBA-GEIGY AG (CH) | 1981-12-30 | — | — | EP | disclosed |
| US-4233299-A | ANTIINFLAMMATORY AGENTS, ANTIPYRETICS | BOEHRINGER INGELHEIM GMBH (DE) | 1980-11-11 | — | — | US | disclosed |
| US-4213980-A | ANTIINFLAMMATORY AGENTS | CIBA-GEIGY CORPORATION (US) | 1980-07-22 | — | — | US | disclosed |
| US-4213980-A | ANTIINFLAMMATORY AGENTS | CIBA-GEIGY CORPORATION (US) | 1980-07-22 | — | — | US | disclosed |
| EP-0003360-A1 | Azathianaphthalene derivatives, process for their preparation, pharmaceutical preparations containing them and their utilisation | CIBA-GEIGY AG (CH) | 1979-08-08 | — | — | EP | disclosed |
| EP-0003360-A1 | Azathianaphthalene derivatives, process for their preparation, pharmaceutical preparations containing them and their utilisation | CIBA-GEIGY AG (CH) | 1979-08-08 | — | — | EP | disclosed |
| EP-0002482-A1 | 4-Hydroxy-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxides, processes for their preparation and pharmaceutical compositions containing them | Dr. Karl Thomae GmbH (DE) | 1979-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171881-A1 | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives | BACE1, BACE2, PSEN1 | KEAP1 1606/4885HTR2C 982/4885AOC3 1289/4885 |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | BACE1, BACE2, APP | KEAP1 1657/4885HTR2C 3772/4885AOC3 3393/4885 |
| US-20230134822-A1 | AMINE COMPOUND, CHEMICALLY AMPLIFIED RESIST COMPOSITION, AND PATTERNING PROCESS | GFER, GNMT, DNER | KEAP1 1002/4885HTR2C 327/4885AOC3 2411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.